Details

---

Manufacturer
Hetero Labs Limited

Registraction Number ​​​​​
MAL20041301AZ


 

Content

• Active Ingredient: Each tablet contains 2.5 mg of letrozole, a non-steroidal aromatase inhibitor that reduces estrogen production, thereby slowing the growth of hormone receptor-positive breast cancer cells.
• Excipients: The tablet includes inactive ingredients such as lactose, magnesium stearate, and other components to form the tablet.
• Appearance: The tablet is typically a film-coated tablet.

Indications

• Adjuvant Treatment: For the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy.
• First-Line Treatment: For first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. 
• Advanced Breast Cancer: For the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Instructions

• Dosage: The usual adult dose is 2.5 mg once daily, taken orally.
• Administration: Swallow the tablet whole with a glass of water. It can be taken with or without food.
• Missed Dose: If a dose is missed, take it as soon as you remember, unless it's almost time for the next dose. Do not take two doses at once to make up for a missed dose.
• Storage: Store below 30°C, in a cool, dry place away from direct sunlight.